Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. inflammatory cells
Show results for
Products
Services
Software
Applications

Companies

News
Articles
Downloads

Refine by
Date

  • Older

Inflammatory Cells Articles & Analysis

14 news found

Profacgen Updated Its E3 Ligase and Target Proteins Development Services

Profacgen Updated Its E3 Ligase and Target Proteins Development Services

As a major modulator of protein homeostasis, UPS is essential in signal transduction, mitophagy, DNA damage repair, inflammatory pathways, endocytosis, and cell cycle progression. More than 600 E3 ligases have been identified, only a few of which have been used in PROTAC design. ...

ByProfacgen


Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting

Seres Therapeutics Presents Preclinical Research on Investigational Microbiome Therapeutic SER-155 at the 2022 European Bone Marrow Transplantation Annual Meeting

Across a variety of preclinical models, SER-155 appears to work by reducing gastrointestinal (GI) inflammation, fortifying the protective GI lining, and promoting immune cell balance in the gut. In cultured human cells designed to mimic the lining of the intestines, SER-155 protected the barrier between the colon and invading pathogens from ...

BySeres Therapeutics, Inc.


Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

Immune-Onc Therapeutics Receives China Investigational New Drug (IND) Approval for the Phase 1 Study of IO-108, a Novel Antagonist Antibody Targeting LILRB2 (ILT4), in Patients with Solid Tumors

ABOUT LILRB2 (ILT4) LILRB2, also known as ILT4, is expressed mostly by myeloid cells, including monocytes, macrophages, dendritic cells, and neutrophils. ...

ByImmune-Onc Therapeutics, Inc.


BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19

BioCardia Announces FDA Approval of Its IND for NK1R+ Mesenchymal Stem Cells for the Treatment of Patients Recovering from Acute Respiratory Distress due to COVID-19

[Nasdaq: BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that the U.S. ...

ByBiocardia, Inc.


Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

Aurealis Therapeutics and Xbiome Enter into a License and Collaboration Agreement for Aurealis Four-in-One Diabetic Foot Ulcer and Inflammatory Disease Cell and Gene Therapy AUP-16 in Greater China

Aurealis Therapeutics, a synthetic biology company developing groundbreaking four-in-one cell and gene therapies and Xbiome, an AI-based microbiome drug development company, today announced that the two companies have entered into an exclusive license and collaboration agreement for the clinical development and commercialization of Aurealis investigational Diabetic Foot Ulcer ...

ByAurealis Therapeutics


New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis

New, late-breaking data at EADV highlights emerging clinical profile of amlitelimab (formerly KY1005) in adults with inadequately controlled moderate-to-severe atopic dermatitis

Amlitelimab is a fully human non-depleting monoclonal antibody that binds to OX40-Ligand, a key immune regulator, and has the potential to be a first-in-class treatment for a range of immune-mediated diseases and inflammatory disorders, including moderate-tosevere atopic dermatitis. By targeting OX40-Ligand, amlitelimab aims to restore immune homeostasis between ...

ByKiadis Pharma NV


Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets

Neuropathix, Inc. Forms Dermique Incorporated its New Wholly Owned Subsidiary for the Ownership and Commercialization of the Company’s Over-The-Counter Cosmeceutical Assets

” LEA™, the Company’s novel small molecule has been shown in preclinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin cells irradiated with UVB-radiation were used in testing to monitor the comparison of the two substances. Although both compounds ...

ByNeuropathix, Inc.


Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders

Neuropathix, Inc. Announces Publication of PCT Patent Application for the Treatment of Radiation Dermatitis and Other Skin Disorders

LEA™, the Company’s novel small molecule has been shown in preclinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin cells irradiated with UVB-radiation were used in testing to monitor the comparison of the two substances. Although both compounds were ...

ByNeuropathix, Inc.


Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi

Hydrogen Peroxide provides Clues to Immunity, Wound Healing, Tumor Biology - Puroxi

Tumors and wounds both generate high levels of hydrogen peroxide, and immune cells responsible for inflammation seek out wounds as well as tumors. But inflammatory cells can often be detrimental. The cells can contribute to a tumor’s ability to grow and invade other tissue, and they can cause chronic inflammation at wound ...

ByPuroxi Pure Water Global Inc.


Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

The Company has conducted scientific comparisons that have been made between two substances: cannabidiol (CBD), a non-psychoactive component of Cannabis, and Atopidine™, a novel, small molecule that has been shown in pre-clinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin ...

ByNeuropathix, Inc.


Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine Versus CBD

The Company has conducted scientific comparisons that have been made between two substances: cannabidiol (CBD), a non-psychoactive component of Cannabis, and Atopidine™, a novel, small molecule that has been shown in pre-clinical testing to have protective and anti-inflammatory properties. The inhibition of release of inflammatory substances from skin ...

ByNeuropathix, Inc.


Lungpacer Medical, Inc. Presentations at American Thoracic Society Conference, Scheduled for May 2020, Philadelphia, Pennsylvania

Lungpacer Medical, Inc. Presentations at American Thoracic Society Conference, Scheduled for May 2020, Philadelphia, Pennsylvania

Increased Presence of Neural Pro-Inflammatory Cells in the Hippocampus After 50 Hours of Gold-Standard Mechanical Ventilation in a Pre-Clinical Pig Model, Bassi, T., et al. ...

ByLungpacer Medical Inc.


This year`s Medical Innovation Summit will highlight neurosciences innovation

This year`s Medical Innovation Summit will highlight neurosciences innovation

A step toward treating Alzheimer’s After 10 years of research into treatment for neuropathic pain – pain caused when damaged nerves in the body send false pain signals to the brain – Mohamed Naguib in the Cleveland Clinic’s anesthesiology department discovered an additional benefit to the treatment: It may also help slow the progression of Alzheimer’s disease and ...

ByInfuseon Therapeutics Inc


FDA Takes Action to Update Sunscreen Testing and Labeling and States Nanoscale Ingredients Are Not Absorbed

FDA Takes Action to Update Sunscreen Testing and Labeling and States Nanoscale Ingredients Are Not Absorbed

The groups submitted information purporting to show that nanomaterials had been found to penetrate cells and trigger inflammatory and immune responses. The Agency has yet formally to respond to the petition, despite addressing the issue obliquely in the myriad of materials released on sunscreen products. ...

ByBergeson & Campbell, P.C.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT